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ABSTRACT 
 
Introduction: The use of multi-ingredient pre-workout supplements has been steadily on 
the rise in the fitness industries. Companies make claims about improvements in 
performance both physically and cognitively for users but seldom provide research to 
back up the claims made about the ingredients or dosages. Purpose: To examine the 
effects of Huperzine-A and Alpha-GPC on short term memory and anaerobic power 
output, post exhaustion compared to caffeine and placebo in healthy college age students. 
Methods: The study was conducted as a double blind, placebo controlled, randomized 
design on 62 healthy adults (N=62 height 68.4 ± 3.5 in., weight 78.5 ± 15.1 kg.). The 
wash out period was a minimum of 48 hours after completion of the familiarization. 
Subjects reported to the exercise physiology lab thirty minutes before testing began and 
consumed either a caffeine, Alpha-GPC and Hup-A, or placebo solution. After the thirty-
minute digestion period subjects performed one computer-based short-term memory test, 
and a thirty-second Wingate anaerobic power test. Subjects then performed an exhaustion 
protocol before repeating the memory and power test. Once all testing was completed 
subjects returned between 2 and 14 days after the last test and repeat the protocol. A 
power analysis was run using G* Power software 3.1.9.2 based from Zeigenfuss et al., 
(2008). The percent change between pre and post was compared across visits using 
ANOVA with repeated measures. Significance was found with an Alpha level P ≤ 0.05 
with Tukey Post Hoc analysis will be used to determine pairwise comparisons. All stats 
were run on IBM SPSS 23. Results: The ANOVA with repeated measures and Tukey 
Post Hoc analysis found there was no significant difference in performance pre to post, 
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between groups, or factoring the percent change pre to post. Conclusion: This result 
suggests there is no physical or mental benefit acutely dosing 600 mg. of Alpha-GPC and 
200 mcg. of Huperzine-A in healthy recreationally active adults. This was the first study 
to look at the two in combination so, the finding is neither supported nor opposed to the 
current body of research. The finding does oppose the logic some supplement companies 
have been using to justify their sales tactics. Future research should investigate the effects 
of a loading period on physical and mental performance. 
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Chapter 1 
 
Introduction 
 
 Background 
The use of supplements in fitness communities has been on the rise for nearly 
the last two decades (Dickinson, Blatman, El-Dash, & Franco, 2014). These 
supplements include but are not limited to Protein shakes, Meal replacement shakes, 
multi-vitamins, post- workout recovery shakes, nootropics (cognitive enhancers), and 
Pre-workouts. Many of these supplements include a long list of ingredients that claim to 
increase bioavailability of the substrate, cause a synergistic effect on the recovery 
process, increase the palatability upon ingestion, increase duration of workout and 
workload ability, or increase mental clarity and focus. Many of the claims about 
increased protein consumption post workout are well researched and backed by 
evidence, the same is not true for many pre-workout ingredient claims (Jeukendrup, & 
Gleeson, 2010) 
 Many different multi-ingredient pre-workout supplements make the same claim 
about being able to increase your strength, focus, workout intensity, and duration but 
very few have any empirical evidence to back up the claims made. One major issue with 
a large portion of these supplements is they may include some ingredients that do have 
some advantageous effects, but the amount is not enough to elicit the desired effect 
typically seen as “Proprietary Blends”. One common example is pre-workouts 
containing caffeine, this is a widely researched supplement that has been found to 
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increase aerobic performance. Supplement companies are highly aware of this claim 
and include 200 milligrams of caffeine and stake the claim “workout harder for longer”. 
This would be true if the person taking the supplement was 40 kg (88 pounds) because 
research shows that to increase aerobic performance with caffeine the ratio must be 5 
milligrams per kilogram of body mass (Pasman, Van Baak, Jeukendrup, & De Haan, 
1995). So, for the average sized adult, this dose would have little to no effect on 
performance. This is one of the most frequently consumed drugs in the world and is 
found in a wide variety of drinks and foods (Gilbert, 1984). This makes caffeine and 
excellent product to compare when examining the potential benefits of a new 
supplement. Caffeine in the correct dose has been shown to be effective in physical and 
mental performance (Ganio, Klau, Casa, Armstrong, & Maresh, 2009, Astorino, & 
Roberson, 2010), but the mechanisms in which caffeine affects performance is still 
unknown and highly speculated (Jeukendrup & Gleeson, 2010). The mechanism of 
action in caffeine is highly debated so, that may lead investigators to explore 
supplements that act on systems they understand, such as the cholinergic systems. The 
use of choline derived supplements has recently sparked the interests of performance 
researchers because of its role in acetylcholine synthesis, which plays an extremely 
important role in muscle contraction and the synaptic functions.  
 The manipulation of free choline in the body through ingestion of choline 
derivatives may prove to be advantageous in physical performance and cognitive 
capability. Alpha-glycerophosphocholine (Alpha-GPC) is a semi-synthetic derivative of 
lecithin that acts by releasing free choline, so it can be synthesized into acetylcholine 
(ACH) and phosphatidylcholine for biosynthesis in the brain (Gatti, Barzaghi, Acuto, 
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Abbiati, Fossati, & Perucca, 1992, Brownawell, 2010). Many studies have shown the 
efficacy of Alpha-GPC in decreasing the cognitive decline in patients with Alzheimer’s 
disease and dementia (Traini, Bramanti, & Amenta, 2013), but few studies have 
investigated its ergogenic effects in exercise performance. Another supplement that has 
recently become a point of interest is Huperzine-A (Hup-A) an ancient Chinese herb 
from the herb Huperzia Serrata (Wang, Yan, & Tang, 2006).  
 Hup-A is a selective, reversible, and potent acetylcholinesterase inhibitor 
(Wang, et al., 2006). Acetylcholinesterase (ACHe) is the enzyme responsible for the 
break-down of ACH in the pre and post synaptic cleft of the neuromuscular and 
intraneuronal synaptic clefts. Once ACH is broken down by ACHe it is returned to the 
presynaptic axon to be synthesized into ACH (Widmaier, Raff, Strang, 2004). Hup-A, 
like Alpha-GPC, was originally used in research on patients with neurodegenerative 
diseases and showed marked improvements on cognition in experimental trails (Wang, 
2006). There is no current research on the effects of Hup-A in physical performance, 
but it has been shown to effectively inhibit ACHe in healthy adults (Morasch, Aaron, 
Moon, & Gordon, 2015). ACHe is the enzyme that breaks down ACH at the post-
synaptic receptors, if this enzyme can be inhibited it may increase the firing rate of the 
synapse. The same principle may apply in the use of Hup-A to manipulate the process 
by which ACH is cycled in the neuromuscular junctions. The potential for increased 
cognitive functioning and physical performance when properly stacking Alpha-GPC 
and Hup-A may prove to be an effective replacement for caffeine in pre-workout 
supplements. 
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The current study proposed to examine the effectiveness of acute 
supplementation of Hup-A and Alpha-GPC, on cognitive performance and physical 
performance in healthy adults before and after an exhaustive protocol, compared to 
Caffeine and Placebo. 
 
Limitations, Delimitations, Assumptions 
 The current limitations, delimitations, and assumptions are made from the pilot 
testing performed prior to the official data collection. As data collection and testing 
proceeds researchers may find some limiting factors in the true experimental design that 
cannot be controlled for. These limitations may include but are not limited to 
controlling for subject eating habits. Subjects will be asked to refrain from any heavy 
meals prior to testing because they may lead to potential issues with proper absorption 
of the supplements. Also, a heavy meal may reduce subject performance during the 
physical performance skewing test results. Problems with cramping, gut pain, or even 
vomiting may occur if over feeding occurs prior to the testing battery. Investigators will 
be sure to ask subjects when their last meal was and make sure they will not have any 
gastrointestinal issues during testing. If the subject feels they cannot perform their best, 
testing will be rescheduled. Consumption of caffeine prior to testing will also be 
discouraged in order to avoid a stacking effect or a potential overdose or synergistic 
effects from the combination of treatment and what subjects may potentially consumed 
on their own. 
Subjects will be asked to refrain from any intense workouts 24 hours prior to 
testing as to avoid a premature fatiguing effect. Researchers will diligently question 
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subjects to make sure there was no previous intense exercise they may skew 
performance results.  
Potential limitations may also include caffeine sensitivities in subjects that are 
non-users, or potential side effects from the dosing of Hup-A. Mild, occasional, side 
effects have been reported with oral supplementation of Hup-A (nausea, vomiting, 
diarrhea). These potential side effects will result in an immediate discontinuation of 
testing with that subject. This study will also be limited by the equipment technology 
and size of the lab hosting the testing protocol.   
Delimitations of the study will be proper dose timing of 30 minutes which will 
begin once the subject has ingested the full treatment and time will be kept by the 
researchers on cite. Physical performance will be collected via a single 30 second 
Wingate using a Monarch cycle ergometer, which has been shown to be a reliable and 
valid means to measure anaerobic power output. A standardized post exhaustive 
protocol recovery time of 5 minutes. Time will begin immediately once the subject 
finished the protocol completely. Subjects will be placed on a computer with noise 
canceling headphones/earplugs to ensure they are not distracted by outside influences 
when short term memory. Short term memory test will be simple and thoroughly 
explained by researchers and warm up rounds will be provided before each test to 
ensure instructions are understood.  
Assumptions of this study are that subjects will come into each testing session 
well rested and will give best efforts in all trials (Investigators will record hours of sleep 
subjects had the previous night). It is also assumed that all subjects will be forth coming 
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with any injuries that may hinder performance during the Wingate, as well as any 
mental clarity issues that may impede cognitive functioning during the trials. 
 
Problem statement  
 Supplement companies put arbitrary amounts of different ingredients and make 
claims about the effects their blend being advantageous for both physical and cognitive 
performance. Many supplements in these products have no research-based evidence that 
suggests they will cause an increase in performance and in some cases, these products 
will contain an ingredient that has been shown to have beneficial effects, but it is an 
insufficient dose. Alpha-GPC and Hup-A have been shown to improve cognitive 
performance and physical performance.  
The purpose of this study is to test the effectiveness of Alpha-GPC and Hup-A 
in a stack supplement on improving cognitive and physical performance post exhaustion 
compared to placebo and caffeine healthy college aged adults. The approach 
investigators will use is an experimental double-blind placebo-controlled protocol. 
 
Hypothesis 
Hypothesis 1 – It was hypothesized that 600 mg of Alpha-GPC and 200 mcg of 
Hup-A would improve anaerobic power output and short-term memory pre and post an 
exhaustive protocol, in healthy college aged students compared to 5 mg/kg of caffeine 
and placebo. 
Hypothesis 2 – It was hypothesized that 600 mg of Alpha-GPC and 200 mcg of 
Hup-A would improve anaerobic power output but not short-term memory pre and post 
7 
exhaustive protocol, in healthy college aged students compared to 5 mg/kg of caffeine 
and placebo. 
Hypothesis 3 – It was hypothesized that 600 mg of Alpha-GPC and 200 mcg of 
Hup-A would improve short term memory but not anaerobic power output pre and post 
an exhaustive protocol, in healthy college aged students compared to 5 mg/kg of 
caffeine and placebo. 
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Chapter 2 
 
Review of Literature 
 
 Background 
Multi-ingredient pre-workouts have become popularized amongst fitness 
enthusiast and athletes at all levels in the health and wellness industry (Dickinson, 
Blatman, El-Dash, & Franco, 2014). Each specific supplement in the recipe having its 
own claim to how it increases performance, most of which make claims regarding 
increases performance, in strength, power, fatigue resistance, and better focus. In 
theory, these combinations of supplements may prove to be advantageous for users but, 
there is very little research as evidence to support the claims made. A. R. Jagim and 
associates published one of few studies analyzing the effects of Multi-Ingredient Pre-
Workout Supplements (MIPS) against placebo (Jagim, Jones, Wright, Antoine, C. 
Kovacs, & Oliver, 2016). One issue with this method is it leaves much room for 
questions about which supplement or combination was responsible for the desired 
effects observed in the research, three main supplements used in the MIPS were 
caffeine, Alpha-Glycerolphosphocholine (Alpha-GPC), and Huperzine-A (Hup-A). 
Caffeine is a widely used substance that has been found to be efficacious for physical 
and mental performance tasks. Multiple systematic reviews on the effects of caffeine on 
sports performance have been published due to its wide use in athletics and ability to 
improve cognitive performance (Ganio, Klau, Casa, Armstrong, & Maresh, 2009, 
Astorino, & Roberson, 2010).  
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Alpha-GPC is a relatively new supplement in the performance world. There are 
very few studies done on the effectiveness of alpha-GPC in peak performance but 
author T. Ziegenfuss suggests it may be effective in increasing peak power, anaerobic 
power, and human growth hormone levels (Ziegenfuss, Landis, & Hofheins, 2008). 
Hup-A comes from the naturally occurring Chinese herb and is a reversible 
cholinesterase inhibitor and comes from Huperzia serrata (Rathee, Chaudhary, Rathee, 
& Rathee, 2008). This herb has been shown in some research to be an effective memory 
booster in monkeys (Ye, Cai, Wang, & Tang, 1999), suggesting the possibly of 
providing similar effects in humans. Here has been little to no research of the effects of 
Hup-A in healthy adults on mental or physical performance. The purpose of this literary 
review is to gauge the efficaciousness of Alpha-GPC and Hup-A against caffeine and 
their possible uses in mental and physical performance in healthy individuals.  
 
Caffeine 
  Caffeine is arguably one of the most widely used drugs in the world according to 
author R.M. Gilbert, 1984. Caffeine is consumed primarily in the form of coffee 54%, 
and tea 43%, but is found in a wide variety of products. Other products with caffeine 
include chocolate, chocolate milk, candy bars, hot chocolate, sodas, and even 
decaffeinated coffee still contains some caffeine (Gilbert, 1984). In 1996, Author J. J. 
Barone reports from the available data that the average consumption in users in the 
United States is 4 milligrams per kilogram of bodyweight (mg/kg) (Barone, & Roberts, 
1996). For a person of about 200 pounds that means they are taking approximately 365 
mg of caffeine a day. 
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Physiological/psychological response to caffeine  
Caffeine has been found to have a wide variety of uses in the average person’s 
day to day life. Many of the uses for caffeine are beyond the scope of this review. While 
there is a plethora of benefits one may receive, some populations experience adverse 
health effects like an acute rise in blood pressure at rest (Robertson, Frölich, Carr, 
Watson, Hollifield, Shand, & Oates, 1978). Robertson, D. et al., (1978) reported a rise 
in mean blood pressure of 10/14 (systolic/diastolic) one hour after a 250 mg dose. If 
chronic use were to become chronically high blood pressure this could pose long term 
health problems. On the contrary, a meta-analysis on of coffee consumption showed 
that 4 cups a day can decrease chances of heart attack, but 10 cups a will return the risk 
back to baseline (Mostofsky, Rice, Levitan, & Mittleman, 2012). Evidence suggests that 
there are some potential benefits with caffeine consumption, and some slight 
complications, which both are dependent on dose and the tolerance of the individual. 
The effects on the physiology are easier to track because investigators can quantify the 
responses simply and uniformly, psychological responses are reasonably less straight 
forward. These responses may pose and issue in caffeine intolerant populations through 
increased levels of perceived anxiety and brain lactate levels, these increases were 
found after subjects were given a dose of 10mg/kg of caffeine (Dager, Layton, Strauss, 
Richards, Heide, Friedman, ... & Posse, 1999). Brain lactate levels were found not to be 
causational to increased anxiety levels by investigators. Hormonal response may be one 
of the factors leading to the perceived anxiety according to Lane J. D. et al., (1990). A 
robust increase in plasma epinephrine and cortisol at a dose of 3.5 mg/kg in both non 
and chronic users, as well as increases in blood pressure and heart rate (Lane, Adcock, 
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Williams, & Kuhn, 1990). This finding is hard to categorize as either psychological or 
physiological because it is sensationalized in both areas simultaneously. For a caffeine 
user with a relatively high tolerance, they may not experience any of the adverse effects 
of the high doses that come in some pre-workout supplements. But, for some 
individuals the side effects caused by high caffeine doses may out-weigh the benefits. 
For caffeine intolerant athletes and exercise enthusiasts use of cholinergic supplements 
may prove to be advantageous. 
Aerobic physical performance 
There are some clear disadvantages to acute and habitual use of caffeine but, 
there are some accompanying advantages to supplementation as well. One study 
provided evidence that caffeine can increase time to exhaustion in cyclists (Costill, 
Dalsky, & Fink, 1978). Researchers had experienced cyclists’ bike until exhaustion on 
stationary bicycle ergometer at 80% of their VO2 max. One trail was placebo controlled 
with decaffeinated coffee, but the other trial was performed with regular coffee 
containing 330mg of caffeine, results showed that the caffeine trail increased the 
average time to exhaustion to 90 minutes, compared to 75 minutes in placebo. Upon 
Further investigation of supplementation for performance, researchers have found the 
ergogenic effects of caffeine on endurance performance are dose dependent. In a review 
of caffeine by authors A. Jeukendrup and M. Gleeson they suggest that endurance 
performance response is dependent on dose relative to body weight. A study by 
researcher W. J. Pasman compared endurance performance time by giving subjects 0, 5, 
9, and 13 mg/kg of caffeine and analyzing the difference in time to exhaustion. They 
found that each dose besides 0 mg/kg had a marked effect increasing performance but 
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no significant increases after 5 mg/kg (Pasman, Van Baak, Jeukendrup, & De Haan, 
1995). The use of caffeine has shown to have an advantageous effect on aerobic 
performance, but there is little evidence suggesting the same for anaerobic performance. 
Anaerobic physical performance 
Once researchers established that the use of caffeine in aerobic performance 
attention turn toward it’s potential to enhance anaerobic performance. this studies 
specifically focused on trained vs untrained populations and a variety of sport-specific 
and non-specific movements. At a dose of 7 mg/kg trained athletes did not see an 
increase in performance during 3, l-minute bouts on a cycle ergometer (Vanakoski, 
Kosunen, Meririnne, & Seppala, 1998). While this study’s focus was to test the effects 
of creatine consumption on athletes, researchers did well in testing the effect of caffeine 
on anaerobic power as well. This study suggests caffeine has little effects on anaerobic 
power output during a 30 second Wingate on a cycle ergometer. Because the Wingate is 
a non-sport specific test, researchers thought to look at the effects of caffeine on a sport 
specific sprint. Researchers J.K.Davis and M. J. Green (2009) report in a review of 
caffeine on anaerobic power that caffeine had no marked effect on sprints for power or 
speed (J. Davis and M. Green, 2009). Similar results were found in a study testing 
division 1 football players during 6, 35-meter sprints. The caffeine taurine mixture 
administered found no improvements on power output compared to placebo (Gwacham 
& Wagner, 2012). Caffeine has shown marked effects in research on aerobic 
performance of athletes but, as previously stated there is little evidence to suggest that it 
has any advantageous effects on anaerobic power output in trained or untrained 
populations.  
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Cognitive Effects 
It is widely accepted that caffeine increases performance in an academic setting, 
but there is limited research for that specific area to support the claim. A large study 
(N=1604) compared the effect of caffeine on introverts versus extroverts. Researchers 
found large doses of caffeine increased intelligence performance tests in extroverts but 
not introverts (Gupta, 1988). Similar effects on working memory were found in 
extroverts at a dose of 200 mg (Smillie, & Gökçen, 2010). Caffeine’s effect of 
individuals is largely found to be dose dependent and there is a threshold that can cause 
issues in memory with non-caffeine users. A dose of 450 mg of caffeine was found to 
decrease performance on memory tasks in non-users but, this high dosage increased 
performance in reaction time testing (Childs & De Wit, 2006). These results suggest 
that there is a bell curve effect on the use of caffeine in the ability to increase cognitive 
performance in individuals, optimal dosing varies based on previous exposure 
(tolerance) and the weight of the user.  
Mechanism of action 
The mechanism of action in which caffeine effects performance is highly 
debated but there are several theories on how it works. Authors Jeunkendrup and 
Gleeson provide several theories on these mechanisms of action. One, is due to 
caffeine’s ability to stimulate fat oxidation (lipolysis) muscles can spare their glycogen 
stores more effectively, this in-turn provides longer lasting energy during endurance 
performance. Another theory is “Possibilities include the handling of ions, inhibition of 
phosphodiesterase leading to an increased concentration of 3’,5 -cyclic adenosine 
monophosphate (cAMP).” This theory is based on the idea that enzyme manipulation by 
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caffeine changes the handling of ions that are used in exercise performance. One 
possible theory is the effect caffeine has on calcium, increasing calcium release from 
the sarcoplasmic reticulum has increases muscle cell excitability. Therefore, one might 
see an increase in ability to contract muscle as well as, increased time of ability to 
contract. Lastly, caffeine is a central nervous system stimulant that has a marked effect 
on “…perceptions of effort or affects the signal transduction from the brain to the 
neuromuscular junction.” If caffeine can manipulate the ability to increase synaptic 
connections at the neuromuscular junctions then that of contractions would increase and 
possibly last longer (Jeukendrup and Gleeson, 2010 p. 269) (Table 1).   
Table 1 
Caffeine Doses and Effects  
  
Use Dosage Effective Source 
Aerobic 330 mg ˄ time to 
fatigue  
Costill et al., 1978, 
5 mg/kg  Pasman et al., 1995 
Anaerobic 7 mg/kg NO Vanakoski et al., 1998 
Cognitive 200 mg ˄ extrovert 
memory 
Smillie, 2010 
Physiological 250 mg- 3.5 mg/kg Robust effect Robertson et al., 1978, 
Lane et al., 1990 
Psychological  10 mg/kg Yes  Dager et al., 1999 
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Importance of Choline 
 The use of Acetylcholine (ACH) in cell function, muscle contraction and 
synaptic function, is well documented. Being the first neurotransmitter to be discovered 
in 1921 by German biologist Otto Loewi (Boeree, 2003) researcher have and in-depth 
understanding of its use in the body and where it is synthesized from. ACH is derived 
from the substrate choline, making choline essential to releasing action potentials all 
through the body, especially in muscle contraction. Authors Jeukendrup and Gleeson 
describe its connection very well “Acetylcholine transmits the electrical potential from 
neuron to muscle cell, leading to the calcium release from the sarcoplasmic reticulum 
and muscle contraction…, The precursor of acetylcholine is choline, a normal 
component of the human diet” (Jeukendrup and Gleeson, 2010). The abundance of 
choline in one’s diet is important because of its lipotropic effects in the liver, choline 
helps prevent lipid accumulation on the hepatocytes (Best and Huntsmen, 1932). Until 
Best and Huntsman began their research initially looking at insulin but, discovered that 
choline inhibits fatty liver accumulation. Before this research, choline was under 
appreciated as a micronutrient essential to one’s health. Thanks to the wide variety of 
foods that contain choline mostly meats, legumes, and dairy products there is a low 
chance one would find themselves in a deficit while eating a well-balanced diet. 
Because of the crucial role ACH plays in the neuromuscular junction, this has led 
researchers to use concentrated forms of choline for supplementation. These 
concentrated forms of choline are broken down more easily into phosphorylcholine 
after ingestion than regular dietary choline. Phosphorylcholine is the metabolically 
active form of choline, it is used in the synaptic cleft through the entire central nervous 
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system (De Ferra, Hagerman, Purpura, Jaeger, Hagerman, & Zenoni, 2016). Author De 
Ferra elaborates well on the function of phosphorylcholine stating “Phosphorylcholine 
migrates to the synaptic nerve endings found throughout the entire central nervous 
system, and in turn increases ACH synthesis and release. ACH is a vastly important 
neurotransmitter present in both brain and muscle tissue. In the brain, ACH plays a key 
role in basically every cognitive function, while in muscle, it is vitally involved in 
muscle contraction, as it is the major neuro-transmitter involved in regulating 
physiological response to exercise.”  
Some examples of choline concentrates are Citicoline (CDP-choline), this 
supplement has shown efficacy in preventing the cognitive decline associated with post 
stroke symptoms (Alvarez-Sabin, 2011). This form of choline concentrate demonstrates 
very important neuroprotective properties that may be useful in increasing cognitive 
performance in healthy individuals. These implications suggest that choline derived 
supplements are not only functional in physical performance, researchers may find use 
for increased cognitive performance as well. Another form of choline concentrate that is 
proving to be advantageous in mental, physical and physiological performance is 
Alpha-glycerophosphocholine.  
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 Alpha-Glycerophosphocholine 
Alpha-glycerophosphocholine (Alpha-GPC) is a natural derivative of the 
substrate choline, which is used in the body to synthesize ACH, a vastly important 
neurotransmitter. Alpha-GPC was developed to act by releasing free choline that in-turn 
will increase ACH and phosphatidylcholine biosynthesis in the brain (Gatti, Barzaghi, 
Acuto, Abbiati, Fossati, & Perucca, 1992). Brownawell et al. (2011) describes it as a 
“semi-synthetic derivative of lecithin. Following oral administration, it is converted to 
phosphorylcholine, a metabolically active form of choline able to reach cholinergic 
synaptic endings where it increases acetylcholine synthesis and release (Brownawell et. 
al., 2011, Lopez et. al., 1991, Trabucchi et al., 1986, Abbiati et al., 1991)”. This suggest 
that ingestion of Alpha-GPC could lead to an increase in plasma choline levels.  
Effects on Physical Performance 
  Alpha- GPC has been hypothesized to increase physical performance in power, 
strength, and aerobic performance, one study found an interesting result on the post 
work-out growth hormone secretion and bench press in males. Researchers Tim 
Ziegenfuss, Jamie Landis, and Jennifer Hofheins tested the Alpha-GPC on seven 
resistance trained men to see its effect on explosive performance and growth hormone 
levels. Subjects were given 600 mg of Alpha-GPC or placebo 90 minutes before 
exercise, then performed an exhaustive squat protocol. After thirty minutes of rest they 
performed a bench protocol to assess peak power, serum samples to assess growth 
hormone secretion were taken immediately, fifteen minutes, thirty minutes, and every 
thirty minutes until the two-hour mark. Researchers found that peak growth hormone 
secretion increased 44-fold in the alpha-GPC trails, and bench press force increased by 
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fourteen percent. Increased bench press power was trending, as well as, lower post 
exercise respiratory exchange rate (Ziegenfuss, Landis, & Hofheins, 2008). 
Investigators conclude that 600 Mg of Alpha-GPC increases bench press force and 
growth hormone secretion and suggest future research be directed toward its effects on 
binding proteins when coupled with resistance training, but the lowering of respiratory 
exchange ratio post exercise has interesting implications to future research as well. 
From the result of this study there is reason to believe that Alpha-GPC may provide and 
ergogenic effect on endurance performance and muscle contractile time. Some 
researchers have taken interest in loading Alpha-GPC and its unique effects on force 
production. Bellar, D. et al., (2015) investigated isometric strength after loading Alpha-
GPC compared to placebo. Research was performed using 13 healthy male college 
students, they were provided with either 600 mg of Alpha-GPC to take daily or a 
placebo after baseline measurements were taken. After a 6-day loading phase of either 
Alpha-GPC or placebo subjects performed an isometric mid-thigh rack pull and 
isometric pushup against force plates and force production was measured in both. 
Researchers found significant increase in the mid-thigh pull strength and a trend toward 
significant change in the push-up. Bellar reports “Magnitude based inferences suggest 
that the A-GPC was 68.3% likely beneficial for increasing upper body isometric force 
and 86.5% likely beneficial for increasing lower body isometric force production.” 
(Bellar, LeBlanc, & Campbell, 2015). Another study examined Alpha-GPC’s effects on 
counter movement jump height, 40-yard dash time, and Wingate anaerobic power 
output compared to placebo. Subjects were given 300 mg of Alpha-GPC administered 
with a sports drink 1 hour before testing. Results found a significant improvement in the 
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counter movement jump compare to placebo but no improvement in the Wingate or 40-
yard dash (Rickard, 2017). Research examining the effects of Alpha-GPC on physical 
performance are sparse and should be further pursued.  
Effects on cognition and mood 
There is evidence to support the claim that Alpha-GPC may also increase 
cognitive performance (Traini, Bramanti, & Amenta, 2013). Traini found that the use of 
cholinergic precursors and acetylcholinesterase inhibitors can improve memory and 
attention in patients with dementia. Due to the vast use of acetylcholine throughout the 
central nervous system and its importance in the neuromuscular junction use for Alpha-
GPC to improve reaction time testing in healthy adults. Researchers found that 
“CRAM” a supplement containing Alpha-GPC (150 mg), choline bitartrate (125 mg), 
phosphatidylserine (50 mg), niacin (vitamin B3; 30 mg), pyridoxine HCl (vitamin B6; 
30 mg), methylcobalamin (vitamin B12; 0.06 mg), folic acid (4 mg), L-tyrosine (500 
mg), anhydrous caffeine (60 mg), acetyl-L-carnitine (500 mg), and naringin (20 mg), 
maintained reaction times pre and post exhaustive protocol (Hoffman, Ratamess, N. 
Gonzalez, Beller, Hoffman, Olson, & Jäger, 2010). As previously stated, 
phosphatidylcholine is the metabolically active form of choline which can be used in 
the neuromuscular junctions to synthesize acetylcholine, an important neurotransmitter 
for proper cell function and specifically for muscle contraction (De Ferra, 2016). In the 
research performed by Hoffman et al. (2010) subjects were given either placebo of 
CRAM supplement in the initial testing once given time to relax and digest they filled 
put a survey fatigue, focus, alertness and energy. Then, subjects performed a reaction 
time test and an exhaustive protocol followed by another survey and reaction test. 
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Hoffman, J. R. et al., (2010) reports that acute supplementation of CRAM has shown 
that subjects maintain feelings of focus and alertness but also maintain reaction times 
pre and post (Hoffman et al., 2010). These results may suggest the increased availability 
of phosphatidylcholine can lead to better performance in cognitive tasks. One issue with 
this study is that it was a multi ingredient supplement so there may be some 
compounding factors contributing the results found. Performance supplements such as 
caffeine are dose dependent (Pasman et al., 1995), dosing is typically measured as 
milligram per kilogram of body weight (mg/kg). Further research on the effects of 
Alpha-GPC relative to body size is needed, it is widely accepted that the consumption 
of Alpha-GPC at relatively high doses is safe for oral consumption (Bronawell, 2011). 
Safety of ingestion 
Researchers must be careful when testing relatively high doses in patients 
because of potential toxicity, Alpha-GPC has been found to be found and is widely 
considered to be safe for consumption in moderate to high doses. The oral ingestion 
toxicity rate has been found to be very high and doses in rats had to be up to 10,000 
mg/kg to exhibit toxic effects or death (Brownawell, 2011). The research suggests that 
Alpha-GPC is safe for consumption at relatively high doses (Table 2).  
Table 2 
Alpha-GPC Dosing and Effects 
   
Use  Dose Timing Effective Source  
Exercise 
performance  
600 mg 90 minutes  ↑ LE Peak, ↑ 
HGH  
Ziegenfuss et 
al., 2008 
600 mg 6-day loading ↑ UE/LE 
isometric 
strength   
Bellar et al., 
2015 
Cognitive 
performance 
150 mg 20 minutes ↑ mood and 
attention?  
Hoffman et al., 
2010 
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Huperzine-A 
Huperzine-A (Hup-A) is a novel alkaloid that comes from the Chinese herb 
Huperzia serrata, and is a selective, reversable and potent acetylcholinesterase inhibitor 
(Wang, Yan, & Tang, 2006). Acetylcholinesterase (ACHe) plays an important role at 
the neuromuscular junction, where acetylcholine (ACH) is released in the synaptic cleft 
it binds to the postsynaptic ACH receptors. Once the action potential is released from 
the motor endplate the enzyme ACHe breaks down the built up ACH into choline and 
acetate. After the breakdown, choline is returned to the presynaptic axon where it is 
reused for the synthesis of new acetylcholine (Widmaier, Raff, Strang, 2004). This well-
established breakdown gives useful insight to how ACH and ACHe are used in the 
neuromuscular junction, but as previously mentioned, these compounds are used 
throughout the entire nervous system. The series of events are similar but there are 
some slight variations in the intraneuronal synapses versus the neuromuscular junctions. 
In the nervous system the synapses are referred to as cholinergic, action potentials 
arrive at preganglionic axon releasing ACH into the “intra-axonal storage site” once the 
ACH crosses the cleft it causes the postsynaptic potential to travel down the ganglionic 
fiber, this is where ACHe begins to break down ACH on the post synaptic membrane 
(Koelle, 1962).  
Effects on cognition 
 There are many similarities between the two systems, both of which are 
affected by the manipulation of ACH and ACHe. Hup-A has been found to improve 
cognitive deficits in the elderly population. It is used for treatments in patients with 
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“Alzheimer disease and vascular dementia, with minimal peripheral cholinergic side 
effects and no unexpected toxicity.” (Wang, 2006).   
Animals 
One study examined the effects of Hup-A on monkeys with scopolamine 
induced memory deficits (Ye, Cai, Wang, & Tang, 1999). In this study 8 monkeys, 4 
young and 4 old, were tested using a delayed response task. They were shown two food 
bowls one which was filled, then they were separated from the bowls by a screen for 
increasingly longer periods of time. The monkeys were intravenously given doses of 
scopolamine to significantly decrease choice accuracy, and then given Hup-A or a 
placebo in the same manner, both were dosed according to body weight. They found 
that Hup-A increased delayed response accuracy in young monkeys given scopolamine 
with peak effect being a dose of .1 mg/kg with a decrease in effectiveness in .2 mg/kg. 
No negative side effects were reported at the administered doses and suggest optimal 
dosing for advantageous effects. 
Humans 
 In one study on healthy adults, researchers tested the effect of 100 and 200 
micrograms of Hup-A on acetylcholinesterase (ACHe) and butyrylcholinesterase 
(BCHe) and neurobehavioral performance. Both doses of Hup-A significantly inhibited 
the release of ACHe but not BCHe, researchers speculate this is due to the selective 
property of Hup-A. No changes were found in the neurobehavioral performance 
(Morasch, Aaron, Moon, & Gordon, 2015). Morasch et al. (2015) states that that dose-
response studies should be done to determine the neuroprotective properties of Hup-A 
and other cholinesterase inhibitors.  
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Safety  
 There have been few trails using Hup-A in healthy adults but there was little to 
no negative side effects associated in this group at dosages of 100- 200 mcg (Morasch 
et al., 2015). Most of the human clinical trials have been done in patient populations 
with Alzheimer’s disease to enhance cognitive ability and alleviate symptoms 
associated with this neurodegenerative disease. In one meta-analysis Wang et al. (2009), 
focuses on the efficacy and safety of Hup-A specifically in patients with Alzheimer’s 
disease. Authors examined 4 large clinical studies where primary outcomes were 
focused on mini-mental state examinations and activities of daily living (Wang, Wang, 
Wei, Song, Zhang, & Chen, 2009). The meta-analysis revealed there were no adverse 
effects on vital signs, blood work, or electrocardiogram readings. Effects were mild to 
moderate in the worst cases scenarios and typically diminished with time, side effects 
included nausea, vomiting, and diarrhea; investigators report it was more likely to 
happen with Hup-A treatment groups than placebo, but it was not statistically 
significant. The recommended doses were between 300-500 mcg a day in groups with 
Alzheimer’s disease, western countries had a growing interest in the use of Hup-A as a 
cognitive enhancer in populations in the normal cognitive range and in the United States 
there were a few supplements that sold it in 100 mcg doses. The statistics from Wang et 
al. suggest that high doses of Hup-A are required to elicit positive effects in populations 
with neurodegenerative diseases.   
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Physical performance  
 Currently there is no research comparing the effects of Hup-A against placebo or 
any other supplement to examine its effects on performance or ability to recover from 
strenuous repeated bouts of exercise (Table 3).  
Table 3 
Hup-A Dosing and Effects 
  
Use  Dose Effective  Source 
Healthy adults’ 
cognitive performance  
100-200 mcg No Morasch, K. C. et al., 2015 
Adults with 
neurodegenerative 
disease 
300-500 mcg ˄ cog. 
Scores 
Wang, B. S. et al., 2009 
Animal trials .1 mg/kg ˅ cog. 
Decline 
Ye, J. W. et al., 1999 
Physical performance N/A N/A None 
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Chapter 3 
 
Methods 
 
Overview 
The purpose of this study was to investigate the synergistic effectiveness of 600 
mg of Alpha-GPC and 200 mcg of Hup-A against 5 mg/kg of caffeine and placebo, in 
increasing anaerobic power output and short-term memory pre and post an exhaustive 
protocol, in healthy college aged students. The study was conducted as a double blind, 
placebo controlled, randomized cross over design. The wash out period was a minimum 
of 48 hours after completion of the testing battery and up to 7 days. Subjects reported to 
the exercise physiology lab thirty minutes before testing began and consumed either the 
caffeine, Alpha-GPC and Hup-A, or placebo solution. After the thirty-minute digestion 
period subjects completed a computer based short term memory test and a thirty-second 
Wingate anaerobic power test. After 3-5 minutes of low intensity pedaling, subjects 
performed a high intensity training battery and then were given 5 minutes of full 
recovery before repeating the first testing battery. Once all testing was completed 
subjects returned between two and fourteen days after the last test and repeated the 
protocol.  
Procedure and instruments 
 Subjects reported to the Exercise physiology lab for two testing sessions thirty-
minutes prior go the beginning of the testing battery. During the first session subjects 
were required to fill out the proper IRB approved informed consent and Health history 
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questionnaire. Subjects were tested for body composition via bioimpedance 
spectroscopy (BIS) on the SOZO (ImpediMed limited Queensland, Australia) for body 
fat and lean mass percentage. 
 In the treatment trials, the subjects were given either solution of 5 mg/kg of 
caffeine (PURCAF caffeine by KAGED muscle, Boise, Idaho), 200 mcg of Hup-A 
(Huperzine-A by Double wood supplements, Philadelphia, Pennsylvania) and 600 mg 
of Alpha-gpc (AlphaSize by Chemi Nutra, Austin, Texas), or a placebo (Karbolyn Fuel 
by EFX Sports, San Jose, California) 30 minutes before the testing battery began. 
Randomization was based on rolling a dice by a third-party investigator. The dice roles 
were assigned to specific treatments by a third-party investigator was responsible for 
supplement dosage, but was not involved with data collection to ensure true double-
blind protocol is followed. All treatments were administered with 8 ounces of water, 
mixed with 1 standard serving of “Blue Razz Watermelon” (Karbolyn Fuel by EFX 
Sports, San Jose, California) carbohydrate supplement to ensure subjects weren’t able to 
tell a difference in flavor across sessions. The Alpha-GPC, Hup-A and caffeine were 
administered in a white flavorless powder form mixed with the carb supplement for 
uniformity across visits.  
 30 minutes after consumption, subjects began the short-term memory 
assessment. Investigators used a computer-based digit span task software to assess short 
term memory called a Digit Span memory test performed on PsychoPy by Python 
software created by Dr. Donald Varakin (Peirce, & MacAskill, 2018). The test took 
subjects roughly 11-13 minutes per session. Subjects were given a verbal explanation of 
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the testing procedure before the start and were allowed 1 trial test. The testing 
procedure is as follows; 
 One number at a time appeared in the center of the testing window for 1 second 
with a 1 second delay before the next number appears. Once each number has been 
displayed a blue enter bar appeared to cue the subject to enter their response. The goal 
was for the subject to enter all the numbers displayed in the order they appeared for 
each sequence. The test was divided into 8 parts of 3 number sequences, the first set of 
3 had 2 digits, the second 3, the third 4, and increased until the last set contained 10 
digits. Scoring was shown as the percent correct of each sequence from the different 
sequence lengths. The average percent was calculated from all sequence percentages as 
a cumulative score. Once subjects complete the full digit span task, they completed a 
Wingate anaerobic power test.  
 The 30 second Wingate anaerobic power test was performed on a Peak Bike 
cycle ergometer (Monark, Ergomedic 894E) where mean, peak, and minimal power 
output were recorded. Subjects were given between a 1 minute and 30 second to 5-
minute warm-up requiring that they stay between 60 and 100 revolutions per-minute 
(rpm) before the onset of the test. Once the warm-up was over subjects were instructed 
to work up to a maximal sprint, at 120 rpm a weight of 7.5% of their weight in 
kilograms dropped and created a constant resistance until the end of the 30 seconds. 
Upon completion the investigator released the resistance and subjects were instructed to 
continue pedaling for 3 minutes as a cool down.  
Peak power output was defined as the most mechanical power output during the 
test in watts, mean power was the average observed throughout the duration of the test, 
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minimal power was the least amount of mechanical power output during the test, all 
values were recorded in watts. Power outputs were calculated in the Monarch analysis 
software. 
 Upon completion of the Wingate anaerobic power test and cool down, subjects 
performed an exhaustive protocol. Three simple exercises were chosen to ensure each 
subject was able to complete them safely and until they are thoroughly fatigued; push-
up, sit-up, and the body weight squat (to the best of their ability). ACSM standards for 
proper form in each movement to ensure all subjects are being tested uniformly (Proper 
form displayed in figures 1-3). Each exercise was performed for 1 minute as fast as 
possible, investigators were watching to ensure correct form is always being used. It is 
assumed that subjects gave their best effort to ensure a fatiguing effect. Protocol was 
chosen as an adaptation of the exhaustive protocol used by Hoffman et al., (2010). Once 
the subject had gone to failure in the exhaustive protocol, they were allowed a 5-7-
minute break plus up to 6 ounces of water for rehydration (without the threat of stomach 
cramping). After the short break subjects will repeat all the testing measurements in the 
same order. Both pre-exhaustion and post-exhaustion scores were compared in all 3 
supplement trials and compared to baseline (Figures 1 – 3). 
 
Figure 1 Correct sit up form 
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Figure 2 Correct squat form 
 
Figure 3 Correct push up form 
  
Data Analysis 
 Descriptive statistics were reported for demographic variables with means and 
standard deviations provided for continuous variables and frequencies and percentages 
provided for categorical variables.  Normality testing was performed on each variable of 
interest using the Shapiro Wilk test. For the cognitive and anaerobic power output 
performance comparisons, a sample size of 10-15 per-group was determined as an 
effective sample size. Based on the number of groups (3) total number of subjects to 
provide 80% power would be 30-45 to detect a difference between visits/groups. Based 
on the results of Ziegenfuss et al., (2008), with an average between groups difference 
being 875 watts (Group 1, 933 watts. Group two 818 watts), significant differences will 
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be found at an alpha level of P ≤ 0.05. Power analysis was run using G* Power software 
3.1.9.2 (Heinrich Heine, Universitat Dusseldorf). Data was analyzed in a two-step 
process. First, subject’s performance was compared pre to post session to find the 
percent change in accuracy in the digit span test and peak power, average power, and 
minimum power output during the 30 second Wingate. These percentages were 
calculated for each of the subject visits familiarization, Placebo, Caffeine, and Hup-
A/Alpha-GPC (treatment). Paired sample T-tests were ran to normalize data, using IBM 
SPSS 23 (Armonk, NY). Second, the changes were compared across groups using a 
repeated measures analysis of variance (ANOVA) using the same software as used for 
the T-test. All visits were compared across visits for each metric. Significance was set 
with an Alpha level of P ≤ 0.05 with Tukey Post Hoc analysis used to determine 
pairwise comparisons significant differences.  
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Chapter 4 
 
Results 
 
Descriptive statistics 
65 healthy adults volunteer to take place in the study, after three subjects were 
dropped from testing due to scheduling conflicts during the allotted time frame. 62 
(N=62 height 1.74 ± 0.089 m., weight 78.5 ± 15.1 kg.) completed the study and were 
used to analyze results. There were two separate sample sizes used to calculate results 
from the two-testing metrics. Digit span memory test had a sample size of N=54 and the 
Wingate Anaerobic power test had a sample size of N=62. Differences in sample sizes 
were due to technical issues with the Lab computer, once the issue was resolved testing 
continued as usual. Each subject was randomly assigned to one of the following groups, 
Placebo (N=21), Caffeine (N=19), and Alpha-GPC/Huperzine-A (N=22) in Power 
output testing. Each group’s results were normalized as a percent of change from pre to 
post among the following metrics of measure, Peak power visit 1 and 2 (PPv1 and 
PPv2), Average power visit 1 and 2 (APv1 and APv2), and Minimum power visit 1 and 
2 (MPv1 and MPv2). Descriptive statistics for the power output percent change are 
shown in table 4. 
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Table 4 
Percent power change descriptive statistics 
Metric Group        Mean ± Std. Dev. Std. Error 
PP v1 Placebo 3.07% ± 10.35% 
8.36% ± 11.90% 
4.15% ± 10.63% 
-0.05% ± 9.63% 
1.98% ± 12.65% 
-0.91% ± 13.82% 
3.3% ± 8.97% 
8.49% ± 8.55% 
3.86% ± 9.46% 
0.44% ± 10.69% 
3.88% ± 8.08% 
2.08% ± 14.92% 
25.75% ± 84.62% 
-4.36% ± 28.04% 
-11.82% ± 50.05% 
-7.99% ± 74.16% 
-0.06% ± 18.40% 
0.77% ± 24.64% 
2.26% 
 Caffeine  2.73% 
 Treatment 2.27% 
PP v2 Placebo 2.10% 
 Caffeine 2.90% 
 Treatment 2.95% 
AP v1 Placebo 1.96% 
 Caffeine 1.96% 
 Treatment 2.02% 
AP v2 Placebo 2.33% 
 Caffeine 1.85% 
 Treatment 3.18% 
MP v1 Placebo 18.47% 
 Caffeine 6.43% 
 Treatment 10.67% 
MP v2 Placebo 16.18% 
 Caffeine 4.22% 
 Treatment 5.25% 
 
 For the digit span memory test score were normalized for percent change in the 
same manner as power output and were coded as digit span cumulative 1 visit 1 and 2 
(DSCv1 and DSCv2) and digit span total visit 1 and 2 (DSTv1 and DSTv2). For the 
digit span the group sizes were slightly different than the power output testing; placebo 
N=20, Caffeine N=16 and Treatment N=18. Descriptive statistics for the digit span 
memory testing percent change are shown in table 5. 
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Table 5 
Digit span percent change descriptive statistics 
Metric Group Mean ± Std. Dev. Std. Error Min. Max. 
DSCv1 Placebo 3.72% ± 15.00% 
4.08% ± 18.53% 
5.78% ± 16.90% 
6.23% ± 15.19% 
3.50% ± 15.96% 
1.09% ± 20.29% 
0.57% ± 4.18% 
0.85% ± 4.36% 
1.20% ± 6.77% 
-0.07% ± 3.97% 
-0.11% ± 4.39% 
1.88% ± 3.99% 
3.35% -27.78% 21.73% 
 Caffeine 4.63% -29.42% 36.85% 
 Treatment 3.98% -30.76% 28.56% 
DSCv2 Placebo 3.40% -16.67% 36.85% 
 Caffeine 3.99% -30.76% 27.27% 
 Treatment 4.78% -53.31% 29.42% 
DSTv1 Placebo 0.93% -9.81% 10.95% 
 Caffeine 1.09% -5.51% 11.92% 
 Treatment 1.60% -6.80% 25.68% 
DSTv2 Placebo 0.89% -10.88% 5.56% 
 Caffeine 1.10% -9.28% 9.03% 
 Treatment 0.94% -4.13% 10.70% 
 
Analysis of Variance  
 An ANOVA was run to determine between group differences in the both digit 
span and power output percent changes. ANOVA found there was no significant 
differences between groups with no main effect in power output percent change as 
shown in table 6.  
Table 6   
ANOVA of power output percent changes   
Metrics F-Value P-Value 
PPv1 1.289 0.283 
PPv2 0.297 0.744 
APv1 1.966 0.149 
APv2 0.428 0.654 
MPv1 2.35 0.104 
MPv2 0.255 0.799 
 
The minimum power output percent change in visit 1 was trending toward significance 
and had the greatest effect size (F= 2.35, P= 0.104) but this was results from the 
familiarization and has no significant bearing on the findings of the study. ANOVA 
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found similar results for the digit span testing, no significance and no effect as shown in 
table 7.  
Table 7   
ANOVA of digit span percent change   
Metrics F-Value P-Value 
DSCv1 0.08 0.923 
DSCv2 0.422 0.658 
DSTv1 0.069 0.933 
DSCv2 1.372 0.263 
 
Tukey Post Hoc Testing  
 Post Hoc testing was run using Tukey analysis to find significant differences 
between groups (Placebo, Caffeine, and Treatment). Because there were no significant 
differences in the ANOVA testing it was highly unlikely there would be a significant 
difference found in Post Hoc. All results for the power output percent change are 
reported in table 8. 
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Table 8      
Tukey Post Hoc Testing Peak Power    
Metric Group Group Mean Difference ± 
Std. Error 
P-Value 
PP v1 Placebo Caffeine -5.29% ± 3.46% 
-1.08% ± 3.34% 
5.29% ± 3.46% 
4.21% ± 3.43% 
1.08% ± 3.34% 
-4.21% ± 3.43% 
-2.03% ± 3.85% 
0.86% ± 3.71% 
2.03% ± 3.85% 
2.88% ± 3.81% 
-0.86% ± 3.71% 
-2.88% ± 3.81% 
-5.19% ± 2.86% 
-0.56% ± 2.75% 
5.19% ± 2.86% 
4.63% ± 2.83% 
0.56% ± 2.75% 
-4.63% ± 2.83% 
-3.44% ± 3.72% 
-1.64% ± 3.58% 
3.44% ± 3.72% 
1.80% ± 3.68% 
1.64% ± 3.58% 
-1.80% ± 3.68% 
30.11% ± 18.89% 
37.57% ± 18.20% 
-30.11% ± 18.89% 
7.46% ± 18.68% 
-37.57% ± 18.20% 
-7.46% ± 18.68% 
-7.93% ± 14.80% 
-8.76% ± 14.26% 
7.93% ± 14.80% 
-0.83% ± 14.64% 
8.76% ± 14.26% 
0.83% ± 14.64% 
0.285 
  Treatment 0.944 
 Caffeine Placebo 0.285 
  Treatment 0.441 
 Treatment Placebo 0.944 
  Caffeine 0.441 
PP v2 Placebo Caffeine 0.859 
  Treatment 0.971 
 Caffeine Placebo 0.859 
  Treatment 0.731 
 Treatment  Placebo 0.971 
  Caffeine 0.731 
AP v1 Placebo Caffeine 0.173 
  Treatment 0.977 
 Caffeine Placebo 0.173 
  Treatment 0.238 
 Treatment Placebo 0.977 
  Caffeine 0.238 
AP v2 Placebo Caffeine 0.627 
  Treatment 0.891 
 Caffeine Placebo 0.627 
  Treatment 0.877 
 Treatment Placebo 0.891 
  Caffeine 0.877 
MP v1 Placebo Caffeine 0.256 
  Treatment 0.106 
 Caffeine  Placebo 0.256 
  Treatment  0.916 
 Treatment Placebo 0.106 
  Caffeine 0.916 
MP v2 Placebo Caffeine 0.854 
  Treatment 0.813 
 Caffeine Placebo 0.854 
  Treatment 0.998 
 Treatment Placebo 0.813 
  Caffeine 0.998 
 
 For the digit span memory test similar results were found, as shown in table 9. 
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Table 9      
Tuckey Post Hoc 
Testing Digit Span  
    
Metrics Group Group Mean difference ± 
Std. Error 
P-Value 
DSCv1 Placebo Caffeine -0.36% ± 5.61% 
-2.06% ± 5.44% 
0.36% ± 5.61% 
-1.71% ± 5.75% 
2.06% ± 5.44% 
1.71% ± 5.75% 
2.73% ± 5.79% 
5.14% ± 5.61% 
-2.73% ± 5.79% 
2.41% ± 5.93% 
-5.14% ± 5.61% 
-2.41% ± 5.93% 
-0.28% ± 1.75% 
-0.63% ± 1.70% 
0.28% ± 1.75% 
-0.35% ± 1.80% 
0.63% ± 1.70% 
0.35% ± 1.80% 
0.04% ± 1.38% 
-1.95% ± 1.33% 
-0.04% ± 1.38% 
-1.98% ± 1.41% 
1.95% ± 1.33% 
1.98% ± 1.41% 
0.998 
  Treatment 0.924 
 Caffeine Placebo 0.998 
  Treatment 0.953 
 Treatment Placebo 0.924 
  Caffeine 0.953 
DSCv2 Placebo Caffeine 0.885 
  Treatment 0.633 
 Caffeine Placebo 0.885 
  Treatment 0.913 
 Treatment Placebo 0.633 
  Caffeine 0.913 
DSTv1 Placebo Caffeine 0.986 
  Treatment 0.927 
 Caffeine Placebo 0.986 
  Treatment 0.979 
 Treatment Placebo 0.927 
  Caffeine 0.979 
DSTv2 Placebo Caffeine 1 
  Treatment 0.319 
 Caffeine Placebo 1 
  Treatment 0.345 
 Treatment Placebo 0.319 
  Caffeine 0.345 
 
Gender differences in percent change 
 Results were analyzed dividing up the genders which were self-reported on the 
health history questionnaire. Sample size for men in power output was N=38 and N=36 
for digit span (weight 85.97±12.65 kg. height 1.78±0.074 m.) and the sample size for 
women for power output was N=24 and N=18 for digit span (weight 66.54±10.06 kg. 
height 1.66±0.062 m.). Each metric (digit span and power output) was analyzed using 
ANOVA and reported in the following tables (Tables 10 – 13).   
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Table 10   
ANOVA of male power output percent changes  
Metrics F-Value P-Value 
PPv1 2.053 0.144 
PPv2 0.567 0.572 
APv1 1.850 0.172 
APv2 1.375 0.266 
MPv1 0.789 0.462 
MPv2 0.916 0.410 
 
Table 11   
ANOVA of female power output percent changes  
Metrics F-Value P-Value 
PPv1 0.079 0.924 
PPv2 0.234 0.794 
APv1 0.310 0.737 
APv2 0.043 0.958 
MPv1 1.626 0.221 
MPv2 1.147 0.337 
 
Table 12   
ANOVA of male digit span percent change  
Metrics F-Value P-Value 
DSCv1 0.019 0.981 
DSCv2 0.206 0.815 
DSTv1 0.485 0.620 
DSCv2 0.880 0.424 
 
Table 13   
ANOVA of female digit span percent change  
Metrics F-Value P-Value 
DSCv1 0.426 0.661 
DSCv2 0.606 0.558 
DSTv1 0.259 0.775 
DSCv2 0.338 0.718 
 
  As shown in tables 10- 13 there was no significant differences within groups or 
between groups with genders separated.  
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 Upon further investigation of the digit span memory test visit 1 pre-exhaustion 
scores and post-exhaustion were compared to the visit 2 pre and post using ANOVA 
with LSD and Tukey Post Hoc multiple comparisons. The scores were not based on 
percent change but what their percent of success was in DSC and DST. Descriptive 
statistics, ANOVA and Post Hoc multiple comparisons were reported in tables 14, 15 
and 16.   
Table 14      
Post exhaustion digit span total score descriptive statistics 
Metric Group N Mean ± Std. Dev.  Std. Error 
V1 DST Placebo 20 0.937 ± 0.062 
0.938 ± 0.044 
0.937 ± 0.067 
0.959 ± 0.032 
0.948 ± 0.041 
0.933 ± 0.045 
0.014 
 Caffeine  17 0.010 
 Treatment 19 0.015 
V2 DST Placebo 20 0.007 
 Caffeine 17 0.009 
 Treatment 19 0.010 
 
Table 15   
ANOVA Post exhaustion Digit Span total 
Metric F-Value P-Value  
V1 DST 0.001 0.999 
V2 DST 2.047 0.139 
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Table 16       
 LSD multiple comparisons  
Metric  Group Group Mean 
difference  
Std. 
Error 
P-Value  
V1 DST  Placebo Caffeine -0.000 0.019 0.963 
   Treatment -0.000 0.019 0.982 
  Caffeine Placebo 0.000 0.019 0.963 
   Treatment 0.000 0.019 0.981 
  Treatment Placebo 0.000 0.019 0.982 
   Caffeine -0.000 0.019 0.981 
V2 DST  Placebo Caffeine 0.011 0.013 0.424 
   Treatment .026* 0.012 0.049 
  Caffeine Placebo -0.011 0.013 0.424 
   Treatment 0.015 0.013 0.26 
  Treatment Placebo -.026* 0.012 0.049 
   Caffeine -0.015 0.013 0.26 
* The mean difference is significant at the 0.05 level 
 As seen in table 16, significance differences were found between groups at alpha 
level 0.049. The difference found was between the treatment and placebo groups based 
on the mean difference score of -0.026 subjects seemed to do better with the simple carb 
supplement in post exhaustion compared to the Supplement provided. Though found 
significant, it does not hold much bearing, the finding is likely a Type 1 Error (False 
Positive). 
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Chapter 5 
 
Conclusion 
  
The results of this study indicate that acute ingestion of 200 micrograms of Hup-
A with 600 milligrams of Alpha-GPC had no effect on cognitive or physical 
performance in a healthy, recreationally active population. Further-more the results 
suggest that after exhaustion the combination of Hup-A and Alpha-GPC may decrease 
cognitive performance. This does not line up with the current body of knowledge about 
the combination of Hup-A and Alpha-GPC, because this is the first study of its kind to 
look at a combination at this dose in a controlled environment with healthy participants. 
As stated by Jay Hoffman, past investigators have suggested that cholinergic 
supplementation may be beneficial for exercise, particularly exhaustive exercise, based 
on the belief that exercise lowers levels of acetylcholine concentrations resulting in 
fatigue and decrease in performance (Hoffman et. al., 2010). Given that information, a 
logical assumption would be that increasing the amount of acetylcholine in the system 
would mitigate the effects of fatigue. But Spector and other investigators found that 
choline supplementation did not improve performance in fatiguing cycling (Spector, 
Jackman, Sabounjian, Sakkas, Landers, & Willis, 1995). These assumptions are widely 
accepted across supplement companies and the same logic is used in nutrition blogs or 
advertisements for pre-workout and nootropic supplements. Companies are making 
these claims based on untested assumption without support in the research. This is a 
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common practice in supplement companies to sell new lines of product to fitness 
enthusiasts (Jagim, et. al., 2016).  
One goal of this study was to put the supplement combination of Alpha-GPC 
and Hup-A to the test and see if there was an ergogenic effect based on the assumptions 
mentioned earlier. Based on the results from this study there was no effect on 
performance. The current body of research for these two supplements are done on an 
individual basis and in most cases are performed on subjects with Alzheimer’s or 
Dementia (Wang, et. al., 2009, & Barbagallo, et. al., 1994). Barbagallo et. al. found that 
the use of Alpha-GPC over a period of 28 days in patients with recent stroke or transient 
ischemic attacks helped psychological recovery. Similarly, a meta-analysis by Wang et. 
al. on the effects and efficacy of Hup-A as a treatment for Alzheimer’s disease. Wang 
found that after an 8-24-week period of ingesting 300-500 micrograms of Hup-A orally 
significantly improved the scores of patients with Alzheimer’s disease. The tests they 
used were the Mini-mental state examination and the Activities of daily living scale. 
The Mini-mental state examination is brief test to screen for Dementia including 
questions on orientation, attention, recall and language (Galea & Woodard, 2005). As 
seen in these two studies each supplement has been shown to be safe and effective in 
increasing cognitive ability in those with neurodegenerative diseases. These studies 
demonstrate there is a use for these supplements in those specific populations but there 
is little other evidence to support the claims made by companies that they are beneficial 
for a healthy population. Because of this gap in literature we investigators felt it was 
necessary to see the potential in a healthy population. Both the mini-mental state exam 
and the activities of daily living scale are self-reported questionnaire. For this study the 
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investigators found it important that the treatment of Alpha-GPC and Hup-A be tested 
using quantifiable results to find if there is an actual change and not the perception of 
change. Another difference is the acute supplementation versus the chronic 
supplementation model.  An acute model was chosen to more accurately represent how 
pre-workout supplements are taken by the recreationally trained population (30-60 
minutes/upon arrival). The previous literature only shows the changes in ill populations 
and none of the testing in Hup-A is done using a demonstrable performance-based test, 
they are all self-reported tests based on self-perception which is not always indicative of 
reality.  
The use of healthy recreationally trained subjects was purposeful because these 
are predominantly the ones being targeted by the supplement companies to buy their 
products. As previously mentioned, these companies are not required to show empirical 
evidence to support their claim that they work (Martinez, Campbell, Franek, Buchanan, 
& Colquhoun, 2016). Even without the proper support for their claim they shamelessly 
market their products. Take this article by Cellucor (a supplement company) for 
example;  
“Studies have also suggested that Huperzine-A can boost your mental energy. 
Taken as a part of your pre-workout supplement, you may have more mental energy and 
a better ability to learn and remember new exercises.” 
 “As a pre-workout supplement, Alpha GPC can help to boost your mental 
energy.”  
“It also helps with athletic performance. A study published in Journal of the 
International Society of Sports Nutrition demonstrated that Alpha GPC supplementation 
resulted in elevated levels of lower body strength output, and researchers confirmed it 
can be useful in promoting overall speed and power.” 
“Finally, Alpha GPC has been said to pair extremely well with other nootropics, 
such as Huperzine A and caffeine, resulting in enhanced benefits.” 
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The only cited research specific to Alpha-GPC or Hup-A in this article references to the 
previously mentioned study by Bellar and colleagues stating it increases lower limb 
isometric strength by an average of 22.2 lbs. 6 days of loading at 600 mg. a day (Bellar, 
2015). The supplement they sell using this article only contains 200 mg preserving. This 
is a classic example of supplement companies making false claims to sell a product. 
 Another comparison performed in the current study was comparing the effects 
of the Alpha-GPC/Hup-A to caffeine dosed at 5 milligrams per-kilogram of 
bodyweight. This dose was chosen because it was found to be efficacious in improving 
both physical and cognitive performance in healthy subjects (Pasman et. al., 1995, 
Davis and Green, 2009, Vanakoski et. al., 1998). Based on the results there was no 
significant difference between groups at any level. The results of this study found that 
neither Alpha-GPC/Hup-A or Caffeine influenced performance compared to placebo 
which is not supported by the current research. This has led the investigators to believe 
there are some design flaws in the method used to test the supplements.  
 The study used a randomized double-blind procedure to make sure there was no 
influence on the subjects from the testers. Optimally, it would not be three separate 
groups, but a randomized cross-over design where each subject was given all three 
treatments. This would control better for inter-subject variations because each subjects’ 
results would be compared against themselves. Other issues with the design was the 
freedom given to subjects on the start time for their Wingate bike sprint. Subjects were 
given the option to start as early as 1 minute and 30 seconds or as late as 5 minutes after 
pedaling at 60-100 rpm. The variation in the warm-up time could have led to the 
consistency issues experienced between visits and between subjects. Another issue is 
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unfamiliarity with the equipment causing issues with executing the test properly even 
under instruction.  
 Gender specific comparisons were analyzed to determine if there was a possible 
gender specific effect. The result suggests there is no gender difference between groups 
implying one gender reacts more to the substances than another. Currently there is no 
published data looking at the differences between genders in these supplements. The 
cause of this may be due to what is known as survivorship bias in research (Brown & 
Goetzmann, 2018). This is based on the idea that in research many times only the 
studies that found that something worked are published. So, if there was a study that 
found that the supplement combination didn’t work it may not have been published due 
to this bias. 
Future Research   
 In the event future investigators try to recreate the current study they should take 
into consideration some of the issues that the primary investigators encountered. One 
issue with a two-visit test was the natural learning effect that subjects had when 
performing these new tasks. In many cases the subject would do better in the second 
Wingate sprint than in the first one. Based on the individuals experience and with 
performing Wingate’s investigators believe that from pre to post the subjects had a 
better understanding of how to perform the testing. So, even after being put in a state of 
exhaustion, subjects would produce higher peak power. To control for this issue, if a 
subject comes in for the first test and scores higher in the post testing than the pre-
testing, they should have to come in for another familiarization test. Another issue is 
proper warm-ups. Investigators should have used the standard 5 minutes at 60-100 rpm 
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warm up to control for variations between subject visits. Lastly, in several studies 
previously mentioned the supplements were given over a span of 28 days or 8 weeks. 
Given this information future investigators should consider examining the effects 
Alpha-GPC and Hup-A after a loading period.  
  
46 
Bibliography 
 
Alvarez-Sabín J, Román GC. Citicoline in vascular cognitive impairment and 
vascular dementia after stroke. Stroke. 2011;42(Suppl 1):S40-S43. 
Astorino, T. A., & Roberson, D. W. (2010). Efficacy of acute caffeine ingestion 
for short-term high-intensity exercise performance: a systematic review. The Journal of 
Strength & Conditioning Research, 24(1), 257-265. 
Barone, J. J., & Roberts, H. R. (1996). Caffeine consumption. Food and 
Chemical Toxicology, 34(1), 119-129. 
Barbagallo, G. S., Barbagallo, M., Giordano, M., Meli, M., & Panzarasa, R. 
(1994). alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic 
attacks. An Italian multicenter clinical trial. Annals of the New York Academy of 
Sciences, 717, 253-269. 
Bellar, D., LeBlanc, N. R., & Campbell, B. (2015). The effect of 6 days of alpha 
glycerylphosphorylcholine on isometric strength. Journal of the International Society of 
Sports Nutrition, 12(1), 42. 
Best CH, Hershey JM, Huntsman ME. The effect of lecithine on fat deposition 
in the liver of the normal rat. J Physiol. 1932 May 30;75(1):56–66.  
Brownawell, A. M., Carmines, E. L., & Montesano, F. (2011). Safety 
assessment of AGPC as a food ingredient. Food and chemical toxicology, 49(6), 1303-
1315. 
Colucci, L., Bosco, M., Ziello, A. R., Rea, R., Amenta, F., & Fasanaro, A. M. 
(2012). Effectiveness of nootropic drugs with cholinergic activity in treatment of 
cognitive deficit: a review. Journal of experimental pharmacology, 4, 163. 
Costill, D. L., Dalsky, G. P., & Fink, W. J. (1978). Effects of caffeine ingestion 
on metabolism and exercise performance. Medicine and science in sports, 10(3), 155-
158. 
Dager, S. R., Layton, M. E., Strauss, W., Richards, T. L., Heide, A., Friedman, 
S. D., ... & Posse, S. (1999). Human brain metabolic response to caffeine and the effects 
of tolerance. American Journal of Psychiatry, 156(2), 229-237. 
Davis, J. K., & Green, J. M. (2009). Caffeine and anaerobic performance. Sports 
Medicine, 39(10), 813-832. 
De Ferra, L., Hagerman, S. L., Purpura, M., Jaeger, R., Hagerman, C., & 
Zenoni, M. (2016). U.S. Patent Application No. 14/993,926. 
Dickinson, A., Blatman, J., El-Dash, N., & Franco, J. C. (2014). Consumer 
usage and reasons for using dietary supplements: report of a series of surveys. Journal 
of the American College of Nutrition, 33(2), 176-182. 
47 
Galea, M., & Woodward, M. (2005). Mini-mental state examination (MMSE). 
Australian Journal of Physiotherapy, 51(3), 198. 
Ganio, M. S., Klau, J. F., Casa, D. J., Armstrong, L. E., & Maresh, C. M. (2009). 
Effect of caffeine on sport-specific endurance performance: a systematic review. The 
Journal of Strength & Conditioning Research, 23(1), 315-324. 
Gatti, G., Barzaghi, N., Acuto, G., Abbiati, G., Fossati, T., & Perucca, E. (1992). 
A comparative study of free plasma choline levels following intramuscular 
administration of L-alpha-glycerylphosphorylcholine and citicoline in normal 
volunteers. International journal of clinical pharmacology, therapy, and toxicology, 
30(9), 331-335. 
Gupta, U. (1988). Personality, caffeine and human cognitive performance. 
Pharmacopsychoecologia. 
Gilbert, R. M. (1984). Caffeine consumption. Progress in clinical and biological 
research, 158, 185-213. 
Gwacham, N., & Wagner, D. R. (2012). Acute effects of a caffeine-taurine 
energy drink on repeated sprint performance of American college football players. 
International journal of sport nutrition and exercise metabolism, 22(2), 109-116. 
Hoffman, J. R., Ratamess, N. A., Gonzalez, A., Beller, N. A., Hoffman, M. W., 
Olson, M., ... & Jäger, R. (2010). The effects of acute and prolonged CRAM 
supplementation on reaction time and subjective measures of focus and alertness in 
healthy college students. Journal of the International Society of Sports Nutrition, 7(1), 
39. 
Jagim, A. R., Jones, M. T., Wright, G. A., Antoine, C. S., Kovacs, A., & Oliver, 
J. M. (2016). The acute effects of multi-ingredient pre-workout ingestion on strength 
performance, lower body power, and anaerobic capacity. Journal of the International 
Society of Sports Nutrition, 13(1), 11. 
Jeukendrup, A., & Gleeson, M. (2010). Sport nutrition: an introduction to 
energy production and performance (No. Ed. 2). Human Kinetics. 
Koelle, G. B. (1962). A new general concept of the neurohumoral functions of 
acetylcholine and acetylcholinesterase. Journal of Pharmacy and Pharmacology, 14(1), 
65-90. 
Lane, J. D., Adcock, R. A., Williams, R. B., & Kuhn, C. M. (1990). Caffeine 
effects on cardiovascular and neuroendocrine responses to acute psychosocial stress and 
their relationship to level of habitual caffeine consumption. Psychosomatic Medicine, 
52(3), 320-336. 
Martinez, N., Campbell, B., Franek, M., Buchanan, L., & Colquhoun, R. (2016). 
The effect of acute pre-workout supplementation on power and strength performance. 
Journal of the International Society of Sports Nutrition, 13(1), 29 
48 
Morasch, K. C., Aaron, C. L., Moon, J. E., & Gordon, R. K. (2015). 
Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults. 
Physiology & behavior, 138, 165-172. 
Mostofsky, E., Rice, M. S., Levitan, E. B., & Mittleman, M. A. (2012). Habitual 
coffee consumption and risk of heart failure: a dose-response meta-analysis. 
Circulation: Heart Failure, CIRCHEARTFAILURE-112. 
Parker, A. G., Byars, A., Purpura, M., & Jager, R. (2015). The effects of alpha-
glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, 
power, speed, and agility. Journal of the International Society of Sports Nutrition, 
12(Suppl 1). 
Pasman, W. J., Van Baak, M. A., Jeukendrup, A. E., & De Haan, A. (1995). The 
effect of different dosages of caffeine on endurance performance time. International 
journal of sports medicine, 16(04), 225-230. 
Peirce, J. W., & MacAskill, M. R. (2018). Building Experiments in PsychoPy. 
London: Sage. 
Rathee, P., Chaudhary, H., Rathee, S., & Rathee, D. (2008). Natural memory 
boosters. Pharmacognosy Reviews, 2(4), 249. 
Rickard, A. J. (2017). α-Glycerophosphorylcholine and the Effects on Anaerobic 
Indices (Doctoral dissertation). 
Robertson, D., Frölich, J. C., Carr, R. K., Watson, J. T., Hollifield, J. W., Shand, 
D. G., & Oates, J. A. (1978). Effects of caffeine on plasma renin activity, 
catecholamines and blood pressure. New England Journal of Medicine, 298(4), 181-
186. 
Shields, K. A., Silva, J. E., Rauch, J. T., Lowery, R. P., Ormes, J. A., Sharp, M. 
H., ... & Jäger, R. (2014). The effects of a multi-ingredient cognitive formula on 
alertness, focus, motivation, calmness and psychomotor performance in comparison to 
caffeine and placebo. Journal of the International Society of Sports Nutrition, 11(1), 
P45. 
Smillie, L. D., & Gökçen, E. (2010). Caffeine enhances working memory for 
extraverts. Biological psychology, 85(3), 496-498. 
Spector, S. A., Jackman, M. R., Sabounjian, L. A., Sakkas, C. A. L. L. I., 
Landers, D. M., & Willis, W. T. (1995). Effect of choline supplementation on fatigue in 
trained cyclists. Medicine and science in sports and exercise, 27(5), 668-673. 
Tinsley, G. M., Hamm, M. A., Hurtado, A. K., Cross, A. G., Pineda, J. G., 
Martin, A. Y., ... & Palmer, T. B. (2017). Effects of two pre-workout supplements on 
concentric and eccentric force production during lower body resistance exercise in 
males and females: a counterbalanced, double-blind, placebo-controlled trial. Journal of 
the International Society of Sports Nutrition, 14(1), 46. 
 
49 
Traini, E., Bramanti, V., & Amenta, F. (2013). Choline alphoscerate (alpha-
glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still 
interesting profile as cognition enhancing agent. Current Alzheimer Research, 10(10), 
1070-1079. 
Vanakoski, J., Kosunen, V., Meririnne, E., & Seppala, T. (1998). Creatine and 
caffeine in anaerobic and aerobic exercise: effects on physical performance and 
pharmacokinetic considerations. International journal of clinical pharmacology and 
therapeutics, 36(5), 258-262. 
Wang, B. S., Wang, H., Wei, Z. H., Song, Y. Y., Zhang, L., & Chen, H. Z. 
(2009). Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the 
treatment of Alzheimer’s disease: an updated meta-analysis. Journal of neural 
transmission, 116(4), 457-465. 
Wang, R., Yan, H., & TANG, X. C. (2006). Progress in studies of huperzine A, 
a natural cholinesterase inhibitor from Chinese herbal medicine 1. Acta Pharmacologica 
Sinica, 27(1), 1-26. 
Ye, J. W., Cai, J. X., Wang, L. M., & Tang, X. C. (1999). Improving effects of 
huperzine A on spatial working memory in aged monkeys and young adult monkeys 
with experimental cognitive impairment. Journal of Pharmacology and Experimental 
Therapeutics, 288(2), 814-819. 
Ziegenfuss, T., Landis, J., & Hofheins, J. (2008). Acute supplementation with 
alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force 
production during, resistance exercise. Journal of the International Society of Sports 
Nutrition, 
  
50 
APPENDICES 
  
51 
 
Appendix A: Informed Consent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
Consent to Participate in a Research Study  
Effects of Alpha-GPC and Huperzine-A on Short 
Term  
Memory, Anaerobic Power Output, Post Exhaustion 
compared to Caffeine and placebo in Healthy 
College Age Students   
 
Key Information  
You are being invited to participate in a research study.  This document includes important 
information you should know about the study.  Before providing your consent to participate, 
please read this entire document and ask any questions you have.    
Do I have to participate?    
If you decide to take part in the study, it should be because you really want to volunteer.  You 
will not lose any benefits or rights you would normally have if you choose not to volunteer.  
You can stop at any time during the study and still keep the benefits and rights you had before 
volunteering.  If you decide to participate, you will be one of about 60 people in the study.  
What is the purpose of the study?    
The purpose of the study is to determine if the two supplements (Alpha-GPC and Huperzine-A) 
will be more effective in improving mental and physical performance compared to a placebo or 
caffeine. Another purpose of this study is to determine if the two supplements will increase 
performance once you are tired after doing multiple exercises. You have been selected to 
participate because you are a healthy person between the ages of 18-40 years old and with the 
proper amount of training history (2 or more years), and are not pregnant.  
Where is the study going to take place and how long will it last?    
The research procedures will be conducted at the Moberly building on Eastern Kentucky 
University’s campus.  You will need to come to Moberly 223 a total of 2 times over the period 
of 2 weeks during the study.  Each visit will take approximately 1 hour to 1 hour and 15 
minutes.  The total amount of time you will be asked to volunteer for this study is 2-3 hours 
over the next 14 days.    
What will I be asked to do?  
For the first visit, you will be required to complete a survey about your current caffeine usage 
and a health history questionnaire. If you are a female participant, you will be required to visit 
the student health center to take a pregnancy test to verify you are not currently pregnant. A 
note from the student health center must be provided to the research team prior to 
2422 
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participating in the testing procedures.  Once the survey is completed, you will be asked to 
perform a simple body composition test to determine body fat and fat free mass. This will 
require you to stand still for one minute while standing on an electronic scale. Lastly, you will 
have your blood pressure and resting heart rate taken by an automatic blood pressure cuff.   
After all paper work and body composition testing is finished, you will be asked to perform a 
memory test. For the test, you will be required to watch a computer screen that will show a 
series of numbers to you. Once all the numbers in the sequence have been displayed, you will 
be asked to type the digits you saw in order, to the best of your ability. The sequences will 
increase from 2 to 10 digits.   
After the memory test has been completed, you will then sit on a stationary bike and be asked 
to pedal for 1 minute at a medium pace. After 1 minute, you will sprint for 10 seconds against 
no resistance then return to a medium pace for 1 minute before working up to a 30 second all 
out sprint against a brake weight of 7.5% of your body weight. You will be allowed a period to 
pedal as a cool down for three minutes before moving on to the next step of testing which will 
include 3 different exercises. The exercises will include: 1 minute of body weight squats, 1 
minute of push-ups (from toes or knees), and 1 minute of sit ups. You will be asked to perform 
as many repetitions of each exercise as you can during each minute. Once all 3 exercises are 
finished, you will rest quietly for 7-10 minutes and can drink water if needed. After the rest 
period, you will repeat the memory test and the bike test.   
  
For the second visit, you will be required to drink one of the following: the combination of both 
AlphaGPC and Huperzine-A, caffeine, or placebo and then sit quietly for 30 minutes while the 
drink digests. Once the digestion period is over, you will be asked to complete the same testing 
process as the first visit. You have an equal chance of being assigned to each drink.  
  
Are there reasons why I should not take part in this study?  
You should not participate in this study if you are under the age of 18 or over 40 years old, 
have chronically high blood pressure (blood pressure greater than 140/90), a high resting heart 
rate (beats per minute greater than 100), a history of metabolic (diabetes), cardiovascular 
(heart disease), or respiratory disease (asthma). If you are or could be pregnant. Also, if 
you have orthopedic issues (joint, muscle, or ligament pain), or mobility limitations, you may 
not want to participate. Lastly, if you have allergies to the any of the supplements you may be 
taking in this study, you will want to refrain from participation.  
  
What are the possible risks and discomforts?  
Possible risks and discomforts that may occur are as follows.   
• Bike test may cause muscle fatigue, heavy breathing, sweating, and mild 
nausea.   
• Exercises may cause muscle fatigue, heavy breathing, sweating, muscle 
soreness, and mild nausea.  
• Supplements may cause increased nervousness, anxiety, mild nausea, and a 
slim chance of diarrhea.   
These discomforts may only last 1-2 minutes or as long as 15 minutes based on each 
individual. Muscle soreness after strenuous exercise is a common side effect but may not occur 
until 1-2 days after testing is complete. This discomfort (if any) will likely not last longer than 3 
days. If you have any further questions/concerns, please contact the research team, contact 
information is located on page 3.   
  
You may, however, experience a previously unknown risk or side effect.  
  
What are the benefits of taking part in this study?    
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You are not likely to get any personal benefit from taking part in this study.  Your participation 
is expected to provide benefits to others by finding if the combination of the previously 
mentioned supplements are as effective or more effective than caffeine.  
  
If I don’t take part in this study, are there other choices?    
If you do not want to be in the study, there are no other choices except to not take part in the 
study.  
  
Now that you have some key information about the study, please continue reading if you are 
interested in participating.  Other important details about the study are provided below.      
  
 
Other Important Details   
  
Who is doing the study?  
The person in charge of this study is John Isaacs, a graduate assistant in the Exercise and 
Sports Science Department at Eastern Kentucky University. Dr. Michael Lane, Dr. Aaron 
Sciascia, and Dr. Donald Varakin will be advising him. There may be other people on the 
research team assisting at different times during the study.  
  
What will it cost me to participate?  
There are no costs associated with taking part in this study.  
  
Will I receive any payment or rewards for taking part in the study?    
You will not receive any payment or reward for taking part in this study.  
  
Who will see the information I give?    
Your information will be combined with information from other people taking part in the study. 
When we write up the study to share it with other researchers, we will write about this 
combined information. You will not be identified in these written materials.  
  
All data will be kept confidential and you will not be identifiable. All records will be kept under 
lock and key. Only those researchers listed above will have access to identifiable information 
and data results.  
  
Can my taking part in the study end early?    
If you decide to take part in the study, you still have the right to decide at any time that you no 
longer want to participate.  You will not be treated differently if you decide to stop taking part 
in the study.  
  
The individuals conducting the study may need to end your participation in the study.  They 
may do this if you are not able to follow the directions they give you, if they find that your 
being in the study is more risk than benefit to you, or if the University or agency funding the 
study decides to stop the study early for a variety of reasons.  
  
What happens if I get hurt or sick during the study?    
If you believe you are hurt or get sick because of something that is done during the study, you 
should call John Isaacs at 502-320-3371 or Dr. Michael Lane at 859-622-1890 immediately. It 
is important for you to understand that Eastern Kentucky University will not pay for the cost of 
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any care or treatment that might be necessary because you get hurt or sick while taking part in 
this study. Also, Eastern Kentucky University will not pay for any wages you may lose if you are 
harmed by this study. These costs will be your responsibility.    
  
Usually, medical costs that result from research-related harm cannot be included as regular 
medical costs.  Therefore, the costs related to your care and treatment because of something 
that is done during the study will be your responsibility.  You should ask your insurer if you 
have any questions about your insurer’s willingness to pay under these circumstances.    
  
What else do I need to know?  
You will be told if any new information is learned which may affect your condition or influence 
your willingness to continue taking part in this study.   
  
We will give you a copy of this consent form to take with you.  
  
 
Consent   
  
Before you decide whether to accept this invitation to take part in the study, please ask any 
questions that come to mind now.  Later, if you have questions about the study, you can 
contact the investigator,  
John Isaacs at 502-320-3371 John_isaacs38@mymail.eku.edu or Dr. Michael Lane at  
Michael.lane@eku.edu (859-622-1890). If you have any questions about your rights as a 
research volunteer, you can contact the staff in the Division of Sponsored Programs at Eastern 
Kentucky University at 859-622-3636.    
  
If you would like to participate, please read the statement below, sign, and print your name.    
  
I am at least 18 years of age, have thoroughly read this document, understand its 
contents, have been given an opportunity to have my questions answered, and voluntarily 
agree to participate in this research study.    
  
  
  
                      
Signature of person agreeing to take part in the study    Date  
  
                
Printed name of person taking part in the study  
  
             
  Name of person providing information to 
subject     
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Appendix B: Caffeine Survey 
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Effects of Alpha-GPC and Huperzine-A on Short Term Memory, Anaerobic Power Output, Post 
Exhaustion compared to Caffeine and placebo in Healthy College Age Students 
Caffeine Consumption survey 
Name___________________  Age______  Weight_________ 
 Date_________ 
Scale of 1 – 10 (1=not at all, 10=can’t be without). How much do you depend on caffeine on a 
daily basis to function properly? ________ 
What form of caffeine do you most often consume?  
_____________________________________________________________________________
_____________________________________________________________________________
________________ 
Give a rough estimate of how many milligrams (Mg) of caffeine you consume daily (Example 1 
cup of coffee = roughly 90-100 mg of caffeine) _________ 
Weekly_____________ 
Intake guidelines chart 
Drinks/Foods Volume Caffeine content mean & 
range 
Filter coffee  125 ml (4 Fl. Oz. cup) 85 (65-135) 
Espresso 30 ml (1 shot) 60 (35-100) 
Soluble Instant Coffee 125 ml (4 Fl. Oz. cup)   65 (35-105) 
Decaffeinated  125 ml (4 Fl. Oz. cup) 3 (1-5) 
Tea 150 ml (5 Fl. Oz cup) 32 (20-45) 
Iced Tea 330 ml (11 Fl. Oz. cup) 20 (10-50) 
Hot chocolate 150 ml (5 Fl. Oz. cup) 4 (2-7) 
Caffeinated soft drinks  330 ml (11 Fl. Oz. cup) 39 (30-48) 
Sugar-free Caffeinated soft 
drinks 
330 ml (11 Fl. Oz. cup) 41 (26-57) 
Energy Drinks  330 ml (11 Fl. Oz. cup) 80 (70-120) 
Pre-workout 1 powder scoop  300 (200-400) 
Chocolate bar 30 g (1 Oz.)  20 (5-36) 
Milk Chocolate  30 g (1 Oz.) 6 (1-15) 
Dark Chocolate 30 g (1 Oz.) 60 (20-120) 
Source (https://www.coffeeandhealth.org/topic-overview/sources-of-caffeine/) 
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Appendix C: Recruitment Script  
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Recruitment script.  
 Thank you for allowing me to come speak to your class about the current research I 
will be conducting in the exercise physiology lab here at Eastern Kentucky University.  
The current study is “Effects of Alpha-GPC and Huperzine-A on Short Term Memory, Anaerobic 
Power Output, Post Exhaustion compared to Caffeine and placebo in Healthy College Age 
Students”. In this study you will be asked to come to the exercise physiology lab for 2, 1-hour 
long visits. In each visit you will be asked to perform a digit span memory test, Wingate 
anaerobic power test, exhaustive protocol, and then repeat the digit span and Wingate tests.  
 In the first visit you will be divided randomly into either a caffeine group, placebo 
group, or treatment group. The group you are assigned to will be blinded to both the 
researcher conducting the tests and you. Each supplement will be in specific doses to provide a 
specific ergogenic effect (caffeine 5mg/kg, Alpha-GPC 600mg and Huperzine-A 200mcg). All 
doses have been tested for safety and been shown to be safe for use in acute dosing.  
All subjects must have a least 2 years’ experience in some form of physical training and be 
between 18-40 years of age. Sign ups are with me and you can contact me at 
John_isaacs38@mymail.eku.edu if you are interested.  
Thank you, 
John Isaacs 
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Appendix D: Data Collection 
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Effects of Alpha-GPC and Huperzine-A on Short Term Memory, Anaerobic Power 
Output, Post Exhaustion compared to Caffeine and placebo in Healthy College Age 
Students 
Primary investigator: John Isaacs. Sub-Investigators: Michael Lane 
Familiarization 
Subject Name______________________(optional)   
 Date_____________ 
Subject number______  Height_______  Weight________ Body 
Comp______ 
Hours of sleep last night_______ 
 Digit span score Pre-test______________ 
Wingate Pre-test-Peak________  Average________ 
 Minimum_________ 
# of sit ups__________  # of push up_________  # of squats __________ 
Digit span score Post-Test___________ 
Wingate Post-Test- Peak____________  Average_________ 
 Minimum___________ 
_____________________________________________________________________________
________ 
Visit 2         
 Date_______________ 
Digit span score Pre-test______________ 
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Wingate Pre-test-Peak________  Average________ 
 Minimum_________ 
# of sit ups__________  # of push up_________  # of squats __________ 
Digit span score Post-Test___________ 
Wingate Post-Test- Peak____________  Average_________ 
 Minimum___________ 
